These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23973211)

  • 1. Fragment-based discovery of focal adhesion kinase inhibitors.
    Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
    Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
    Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors.
    Heinrich T; Seenisamy J; Emmanuvel L; Kulkarni SS; Bomke J; Rohdich F; Greiner H; Esdar C; Krier M; Grädler U; Musil D
    J Med Chem; 2013 Feb; 56(3):1160-70. PubMed ID: 23294348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).
    Moffett K; Konteatis Z; Nguyen D; Shetty R; Ludington J; Fujimoto T; Lee KJ; Chai X; Namboodiri H; Karpusas M; Dorsey B; Guarnieri F; Bukhtiyarova M; Springman E; Michelotti E
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7155-65. PubMed ID: 22014550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
    Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
    Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM
    Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of B. anthracis N(5)-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening.
    Lei H; Jones C; Zhu T; Patel K; Wolf NM; Fung LW; Lee H; Johnson ME
    Bioorg Med Chem; 2016 Feb; 24(4):596-605. PubMed ID: 26740153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes.
    Wassermann AM; Kutchukian PS; Lounkine E; Luethi T; Hamon J; Bocker MT; Malik HA; Cowan-Jacob SW; Glick M
    J Med Chem; 2013 Nov; 56(21):8879-91. PubMed ID: 24117015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
    Dao P; Jarray R; Le Coq J; Lietha D; Loukaci A; Lepelletier Y; Hadj-Slimane R; Garbay C; Raynaud F; Chen H
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4552-6. PubMed ID: 23845217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in the fragment-based drug discovery].
    Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
    Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.
    Giordanetto F; Wållberg A; Cassel J; Ghosal S; Kossenjans M; Yuan ZQ; Wang X; Liang L
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6665-70. PubMed ID: 23010274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based discovery of substituted 4,5'-bithiazoles as novel DNA gyrase inhibitors.
    Brvar M; Perdih A; Renko M; Anderluh G; Turk D; Solmajer T
    J Med Chem; 2012 Jul; 55(14):6413-26. PubMed ID: 22731783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Native State Mass Spectrometry, Surface Plasmon Resonance, and X-ray Crystallography Correlate Strongly as a Fragment Screening Combination.
    Woods LA; Dolezal O; Ren B; Ryan JH; Peat TS; Poulsen SA
    J Med Chem; 2016 Mar; 59(5):2192-204. PubMed ID: 26882437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based screening using surface plasmon resonance technology.
    Perspicace S; Banner D; Benz J; Müller F; Schlatter D; Huber W
    J Biomol Screen; 2009 Apr; 14(4):337-49. PubMed ID: 19403917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
    Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based fragment hopping for lead optimization using predocked fragment database.
    Lin FY; Tseng YJ
    J Chem Inf Model; 2011 Jul; 51(7):1703-15. PubMed ID: 21627327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-based discovery of JAK-2 inhibitors.
    Antonysamy S; Hirst G; Park F; Sprengeler P; Stappenbeck F; Steensma R; Wilson M; Wong M
    Bioorg Med Chem Lett; 2009 Jan; 19(1):279-82. PubMed ID: 19019674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.